14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CALI vs ABEO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over BlackRock ETF Trust II iShares Short-Term California Muni Active ETF (CALI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CALI carries a Unified Composite Score of 53.0/100 (HOLD) at $50.14 (N/M Forward P/E, N/A operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin).
Composite vs. Pillar Nuance: While CALI currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. ABEO 49.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. N/A operating margin) and revenue trajectory (+2745.0% vs. N/A YoY).
Technical & Structure Timing Caution: CALI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.8); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CALI vs ABEO. Trailing 12-month operating profitability (CALI N/A vs ABEO -186.1%) and valuation multiples (CALI N/M vs ABEO 18.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $167.4M market capitalization and -186.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CALI vs ABEO Key Questions & Quantitative Answers
As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over BlackRock ETF Trust II iShares Short-Term California Muni Active ETF (CALI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CALI carries a Unified Composite Score of 53.0/100 (HOLD) at $50.14 (N/M Forward P/E, N/A operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin). Composite vs. Pillar Nuance: While CALI currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. ABEO 49.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. N/A operating margin) and revenue trajectory (+2745.0% vs. N/A YoY). Technical & Structure Timing Caution: CALI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.8); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABEO leads the Growth & Scale pillar: CALI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). On trailing 12-month operating scale, CALI generates N/A in USD-normalized revenue versus $39M for ABEO. In operating R&D and SG&A reinvestment, CALI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.
ABEO screens cheaper on headline valuation multiples. CALI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CALI (N/A ROE) versus ABEO (-42.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CALI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 1% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.